Publications

• Stacey L. Worthy, et al., #MeToo Meets the Emergency Room: Providing and Paying for Care After a Sexual Assault, 13:175 St. Louis U. J. Health L. & Pol’y 175 (2020).

• Stacey L. Worthy, et al., The Clinical and Economic Impact of the Early Detection and Diagnosis of Cancer, 14.2 Health L. & Pol’y Brief 2 (2020).

• Stacey L. Worthy, et al., Potential Impact of Texas et al v United States on Persons with Substance Use Disorder, ABA Health eSource (October 2018).

• Stacey L. Worthy, et al., The Compounding Conundrum: How Insufficient Delineation of Regulatory Responsibility Has Created a Need for State and Federal Compounding Drug Law Reform, 72(3) Food & Drug L.J. (2017).

• Stacey L. Worthy & Gary Branning, Emphasize Shared Decision-Making Between Physicians & Patients to Improve Diabetes Outcomes, 10(5) Am. Health & Drug Benefit J. 242 (2017).

• Stacey L. Worthy, et al., Now or Never: The Urgent Need for Action Against Unfair Coverage Denials for Quality Health Care, 48 Loy. U. Chi. L.J. 1041 (2017).

• Stacey L. Worthy, Don’t Sell Out Safety: A Call to Preserve Risk Evaluation and Mitigation Strategies to Reduce Harm to Patients and the Public in the U.S., 9:2 J. Pharmaceutical Pol’y & Practice 1 (2016).

• Stacey L. Worthy, et al., A Call for Differential Diagnosis of Non-Specific Low Back Pain to Reduce Opioid Abuse, 101(2) J. Med. Reg. 39 (2015).

• Michael C. Barnes & Stacey L. Worthy, Evaluating Motives: Two Simple Tests to Identify and Avoid Entanglement in Legally Dubious Urine Drug Testing Schemes, 11 J. Opioid Mgmt. 89 (2015).

• Stacey L. Worthy, et al., Abuse-Deterrent Formulations: Transitioning the Pharmaceutical Market to Improve Public Health and Safety, 6(2) Therapeutic Advances in Drug Safety 67 (2015).

• Michael C. Barnes & Stacey L. Worthy, Applying Lessons from the Opioid Abuse Epidemic to Protect Consumers from Gray Market Biologics, 29 Notre Dame J.L. Ethics & Pub. Pol’y 375 (2015).

• Michael C. Barnes & Stacey L. Worthy, Achieving Real Parity: Increasing Access to Treatment for Substance Use Disorders Under the Patient Protection and Affordable Care Act and the Mental Health and Addiction Equity Act, 36 U. Ark. Little Rock L. Rev. 555 (2014).

• Stacey L. Worthy & Jason F. Kozak, Follow-on Biologics: Protecting Consumers through State Pharmacy Law in Light of FDA Actions, 17 Quinnipiac Health L.J. 207 (2014).

• Michael C. Barnes & Stacey Sklaver, Active Verification and Vigilance: A Method To Avoid Civil and Criminal Liability When Prescribing Controlled Substances, 15 DePaul J. Health Care L. 93 (2013).